Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM MULTI SYMPTOM RELIEF versus LOMOTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM MULTI SYMPTOM RELIEF versus LOMOTIL.
IMODIUM MULTI-SYMPTOM RELIEF vs LOMOTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, thereby allowing for greater absorption of water and electrolytes. Simethicone reduces surface tension of gas bubbles, facilitating their coalescence and expulsion.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription up to 16 mg/day). Route: oral.
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 11 hours) in plasma; in clinical context, it supports twice-daily dosing for chronic diarrhea.
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Fecal: ~60% (loperamide and metabolites); Renal: ~1-2% (unchanged loperamide and glucuronide conjugates); Biliary: minimal, as loperamide undergoes extensive enterohepatic recirculation.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Category C
Category C
Antidiarrheal
Antidiarrheal